Pharmaceuticals

EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

by

NORTH CHICAGO, Ill., May 19, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including … Read more

Cell Isolation Market worth $8.2 billion

by

CHICAGO, May 19, 2023 /PRNewswire/ — The cell isolation industry is poised for significant advancements in the near future. With the rapid progress in biotechnology and regenerative medicine, there is a growing need for precise and efficient methods of isolating specific cell populations. Cell isolation techniques enable researchers and clinicians to obtain pure and viable … Read more

USD 306.2 Billion Growth in Active Pharmaceutical Ingredients Market Size

by

NEW YORK, May 19, 2023 /PRNewswire/ — As per Facts and Factors study, the global active pharmaceutical ingredients market size was worth around USD 191.3 billion in 2022 and is predicted to grow to around USD 306.2 billion by 2030 with a compound annual growth rate (CAGR) of roughly 4.7% between 2023 and 2030. Report … Read more

Euro PCR 2023 | Resultado a los 6 meses del estudio SMART

by

– Euro PCR 2023 | Resultado a los 6 meses del estudio SMART: control satisfactorio de la PA logrado con una carga de medicación reducida PARÍS, 19 de mayo, 2023 /PRNewswire/ — El 17 de mayo de 2023, se publicó el resultado de seis meses del estudio SMART (Sympathetic Mapping/Ablation Renal Nervers for Treatment of Hypertension … Read more

EuroPCR 2023 | 6-Monats-Ergebnisse der SMART-Studie: zufriedenstellende Blutdruckkontrolle bei reduzierter Medikamentenbelastung erreicht

by

PARIS, 19. Mai 2023 /PRNewswire/ — Am 17. Mai 2023 wurde das Sechsmonatsergebnis der SMART-Studie (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811) auf der Late Breaking Clinical Trial-Konferenz veröffentlicht, die bahnbrechende Ergebnisse auf dem Gebiet des Bluthochdrucks liefert. Unter der Leitung von Professor Huo Yong und mit SyMap Medical (Suzhou) Ltd. als Sponsor … Read more

Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society

by

SAN DIEGO, May 19, 2023 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its participation in the Nasdaq Closing Bell Ceremony on May 19, 2023. The event will serve as a commemoration of National Brain Tumor Awareness Month … Read more

Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023

by

–  New investigational data evaluating Fexuprazan in a Korean clinical trial program for healing erosive esophagitis (EE) regardless of food intake, and in a Chinese pivotal clinical trial program for the treatment of EE SEOUL, South Korea and CHICAGO, May 19, 2023 /PRNewswire/ — Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the … Read more

AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE

by

EMERYVILLE, Calif., May 19, 2023 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, (“Croda”) for the supply of sustainable squalene. … Read more

Positive Results from Interim Analysis of ‘GEN-001’ Plus avelumab (Bavencio®) Phase II Trial

by

SEOUL, South Korea, May 19, 2023 /PRNewswire/ — Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim analysis. Using a single-strain bacteria in combination with avelumab (Bavencio®) … Read more

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

by

STOCKHOLM, May 19, 2023 /PRNewswire/ — Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog alfa, a new class of high-sustained FVIII developed for the treatment of people with haemophilia A of all age groups. The application is based on data from the pivotal XTEND-1 … Read more